Moreover, the clinical trial using relatlimab (anti-LAG-3 antibody) in combination with nivolumab and chemotherapy compared to chemotherapy in combination with nivolumab used in the first line of treatment in NSCLC patients is currently recruiting (NCT04623775). This evidence concerns the gene LAG3 and non-small cell lung carcinoma.